The global market for drug delivery technologies totaled $54.7 billion in 2017. The market should reach $85.8 billion by 2022, growing at a compound annual growth rate (CAGR) of 9.4% during 2017-2022
NEW YORK, Jan. 31, 2018 /PRNewswire/ -- The global market for drug delivery technologies totaled $54.7 billion in 2017. The market should reach $85.8 billion by 2022, growing at a compound annual growth rate (CAGR) of 9.4% during 2017-2022.
Read the full report: https://www.reportlinker.com/p02720113
• North American market for drug delivery technologies totaled $20.4 billion in 2017. The market should reach $34.3 billion by 2022, growing at a CAGR of 10.9% during 2017-2022.
• European market for drug delivery technologies totaled $15.0 billion in 2017. The market should reach $22.3 billion by 2022, growing at a CAGR of 8.3% during 2017-2022.
Chapter 1: Introduction
Study Goals and Objectives
The drug discovery tools market is a multibillion-dollar industry and comprises biomedical and pharmaceutical research. This market is on the rise due to continued demand for globally accepted drugs that are efficacious, of high quality and affordable.
The drug discovery tools industry includes all products dealing with cellular, genomic, proteomic analysis and systemic study concerning the human body, in order to aid in the development of novel drug candidates. BCC Research's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for drug discovery tools.
This report explores present and future strategies within the drug discovery tools market, including highthroughput screening, bioanalytical instruments for drug discovery, cell-based assays and reagents for drug discovery, proteomics drug discovery, genomics drug discovery, bioinformatics as a platform for drug discovery and other technologies. This report will also discuss the innovations, challenges and the needs of the market, as well as classifications, comparisons and usage of these tools.
A detailed analysis of drug discovery tools industry structure has been conducted. Revenues are broken down by region, while sales figures are estimated for the five-year period from 2017 through 2022. Applications of drug discovery tools and significant patents and their allotments in each category are also covered in this report.
Reasons for Doing This Study
The drug discovery process is a prolonged one and consumes a major portion of drug development costs. Usage of cutting-edge technologies have helped to develop all aspects of the pharmaceutical and biotechnology industries. Drug discovery tools, such as high-throughput screening, bioanalytical tools, proteomics tools and computational tools are some of the widely used technologies.
The expansion of the drug discovery market is due to the increasing application of these tools in developing a mechanistic approach to drug delivery, lead identification, validation and targeting. Progressive pharmaceutical and biopharmaceutical companies are now exploring the advantages of drug discovery tools as part of the production process, which has led to a reliable revenue stream.
R&D spending, along with increasing competition, patent expirations and new technologies are giving direction to the market as companies focus on customer needs.
Acquisition strategies and collaborations by companies are also covered in this report, with further discussion on the strength and weaknesses of each type in light of the new technologies, growing competition, and changing customer needs.
Scope of Report
In recent years, the drug discovery market has seen remarkable discoveries and rapid progress. This report focuses on the global market of drug discovery tools and provides an updated review to include basic design and its applications in various disease areas.
The drug discovery tools include highthroughput screening, bioanalytical tools, proteomics, genomics, bioinformatics and few others, like metabolomics, combinatorial chemistry, nanotechnology and system biology. These tools are further classified into subcategories for the purpose of this report. The five main application areas described in this report concern different cancer types, cardiovascular diseases, immunological diseases, neurological diseases and others which includes metabolic, endocrinology and genetic diseases.
The report also covers market by end user for drug discovery tools: biopharmaceutical companies, research, academia and Others, including contract research organizations.
This BCC Research report is global in scope and includes analysis of the various regulatory environments, new products and advancements, market projections and market share.
Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the drug discovery tools market. The geographical regions covered are the U.S., Europe and the emerging markets of India, China, Japan, South Korea, Taiwan, Africa, Australia, New Zealand, Canada, among others.
Key players in the drug discovery market include Thermo Fisher Scientific, Agilent Technologies Inc., Shimadzu Corp., Bruker Corp., Illumina Inc., F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc. and Merck KGaA (including EMD Millipore and Sigma Aldrich).
Information Sources
Many companies were surveyed to obtain data for this study, including manufacturers and end users of drug discovery technologies. Data were gathered from various industry sources. BCC Research spoke with industry officials, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
Methodology
Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers and users of drug discovery tools products. Projections were based on estimates, such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Geographical Breakdown
In this report, the geographic regions considered for market analysis include, and only include:
North America
• United States
• Mexico
• Canada
Europe
• France
• Germany
• Italy
• U.K.
• Spain
• Sweden
• Austria
• Denmark
• Switzerland
• Belgium
• Netherlands
• Czech Republic
• Croatia
• Finland
• Ireland
• Norway
Emerging Markets
• China
• India
• Japan
• Singapore
• South Korea
• Taiwan
• Africa
• Australia
• New Zealand
• Israel
• Middle East countries
Drug Discovery Technologies, by Type
High Throughput Screening
Bioanalytical Instruments for Drug Discovery
HPLC Equipment and Accessories
MS Equipment and Accessories
UV-Vis Spectroscopy and Others
Nuclear Magnetic Resonance
Microscopy
X-ray Crystallography
Cell-based Assays and Reagents for Drug Discovery
Cell-based Assays
Cell Biology Reagents
Proteomics Drug Discovery
Two-dimensional Gel Electrophoresis
Protein Microarray/Protein Chip
Genomics Drug Discovery
Polymerase Chain Reaction
Deoxyribonucleic Acid Microarrays
Ribonucleic Acid Interference
Next-Generation Sequencing
Epigenetics
Bioinformatics as Platform for Drug Discovery
Other Drug Discovery Technologies
Metabolomics
Combinatorial Chemistry
Systems Biology
Nanotechnology
Drug Discovery Technologies, by End User
Biopharmaceutical Companies
Research and Academia
Others
Drug Discovery Technologies, by Application
Cancer Diseases
Cardiovascular Diseases
Immunological Diseases
Neurological Diseases
Others (metabolic, endocrinology and genetic disease fields)
Chapter 2: Summary and Highlights
The drug discovery industry has witnessed growth in the past few years owing to progress in biochemical, translational and molecular studies in biomedical research. These tools are commercially employed in the development of novel and efficient drug candidates.
The booming healthcare sector and increased government funding has aided significant growth in the biomedical industry. The delineation of mechanistic details and the underlying mechanisms of drug target interaction have paved the way for more efficient and accurate therapies. The biopharmaceutical industry and various research institutes are conducting exhaustive research in the field of drug discovery.
The expanding field of drug discovery and development is allowing researchers to focus on discovering important lead compounds for various forms of cancer and other diseases. Globally, biopharmaceutical companies and research institutes are exploring several molecular and biochemical aspects to develop mechanistic approaches for drug discovery.
Various tools such as high-throughput screening, proteomics and genomic tools, including quantitative reverse transcription polymerase chain reaction (qRT-PCR), next generation sequencing (NGS) and many others, are being widely used for cellular analysis.
In the last decade, the drug discovery tools market has witnessed increased usage in the biomedical industry. Applications are proteomics, next-generation sequencing and high-throughput screening tools that target cancers and other diseases, including autoimmune diseases.
A rise in R&D, the growing incidences of various life-threatening diseases and the increasing global population are all market drivers. Companies are focusing on enhancing biomedical research and advancement of superior technologies in order to provide better quality of treatment and therapies. One industry source described the current drug discovery process as driven by the computational method using bioinformatic tools, followed by drug innovation in the pharmaceutical industry, plant-derived drug discoveries and, lastly, through the translation of molecules.
Collaborative efforts of researchers and the pharmaceutical industry are establishing various promising future drug candidates. Drug discovery find applications in cardiovascular, neurological, cancer and other disease areas. Some key players in this space include Thermo Fisher Scientific, Shimadzu Corp., Illumina Inc. and Bio-Rad Laboratories Ltd. Major end users of these products are research centers, academic institutions, government and private laboratories, as well as pharmaceutical, biotechnology companies and contract research organizations.
Read the full report: https://www.reportlinker.com/p02720113
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article